[18/07/2007] Update 13 August 2007
Trading Update Q2: turnover +13%Arseus and OTC France confirm turnaround with double digit growth in Q2
19 July 2007 (5:40 PM CET) - The consolidated turnover of the Omega Pharma group amounted to 292 million euro in the second quarter, i.e. 13 per cent above the figure for the comparable period last year. Both Consumer Health (OTC) and Arseus (B2B) demonstrated double digit growth in the second quarter.
In the Consumer Health division, the strong performance of Omega Pharma France deserves particular attention.
In the Arseus division, Arseus Medical registered a growth in turnover of no less than 20 per cent.
Arseus is accelerating its IPO planOn 4 July 2007 Arseus announced that it is now targeting its IPO for 2007. Initially this operation was scheduled for 2008. Arseus is ready to assume the consolidator role in the growing, fragmented Professional Health market in Europe. Read more.
The Initial Public Offering of Arseus will be guided by an international bank consortium, with UBS and KBC Securities acting as Global Coordinators and Joint Bookrunners, and with Bank Degroof, ING Belgium and Kempen & Co as Co-Lead Managers.
